Background

Worldwide, breast cancer is the most common malignancy in women. The American Cancer Society estimated that there were 252,710 new breast cancer cases and 40,610 breast cancer deaths occurred in the United States, in 2017 (1). Although breast cancer is the most commonly diagnosed cancer, it is the second causes of death. With the invention of therapeutic drugs, especially targeted drugs, most patients with early stage breast cancer were cured, the patients with metastases also had a notable improvement of progression-free survival (PFS) and overall survival (OS).

Human epidermal growth factor receptor 2 (HER2) has been identified as oncogenes in about 20% of all breast cancer patients. Since the last 1980s, many studies had identified that breast cancer, with HER2-positive had a more aggressive biology and were associated with poorer outcomes (recurrence and survival) (2-4). Since 1998, the first anti-HER2 agent (trastuzumab) got into clinical, which significantly improved the prognosis of HER2-positive breast cancer patients in both the early stage and metastatic settings.

In the last 20 years, multiple anti-HER2 agents span a number of drug classes stepped into clinical practice, included the monoclonal antibodies (trastuzumab and pertuzumab), the small-molecule intracellular tyrosine kinase inhibitors (lapatinib and neratinib) and the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1).

In this article, we will review a number of trials, primarily in phase III, in HER2-positive metastatic breast cancer (MBC) which have indicated significant improvement outcomes with anti-HER2 therapy in the first-line setting and beyond (Table 1) and constantly change clinical practice, then, discuss some new targeted agents in the current management and anti-HER2 therapy in HER2 low-or non-expression breast cancer.

First-line therapy

**Trastuzumab**

Trastuzumab, a murine monoclonal antibody, directed...
against the extracellular domain of HER2, is the first anti-HER2 antibody approved by Food and Drug Administration (FDA) in 1998 for the treatment of patients with HER2-positive MBC (19).

The first phase III clinical trial result provided by Slamon et al. (5) in 2001, demonstrated trastuzumab increased the clinical benefit of first-line chemotherapy in MBC that overexpresses HER2. Patients with HER2-positive MBC were randomly divided into two group in the first-line therapy, one was chemotherapy with trastuzumab (n=235) and the other was chemotherapy alone (n=234). A significant improvement in time to progression (TTP) (7.4 vs. 4.6 months; P<0.001) and OS (25.1 vs. 20.3 months; P=0.01) had been obtained at a median follow up of 30 months. The most important adverse event was cardiac dysfunction. Higher rates of cardiac dysfunction were seen with the combination of anthracycline and trastuzumab than anthracycline alone (27% vs. 8%). Though, there was also higher in paclitaxel-trastuzumab than paclitaxel alone (8% vs. 1%), the overall rates were low.

Then, trastuzumab were tested in combination with several chemotherapy drugs. Robert et al. (6) randomized

<table>
<thead>
<tr>
<th>Trial</th>
<th>n</th>
<th>Treatment arms</th>
<th>Setting</th>
<th>Response rate, %</th>
<th>TTP/PFS, months</th>
<th>OS, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slamon et al. (5)</td>
<td>469</td>
<td>Trastuzumab + chemotherapy</td>
<td>First line</td>
<td>50</td>
<td>7.4</td>
<td>25.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemotherapy</td>
<td></td>
<td></td>
<td>32*</td>
<td>4.6*</td>
</tr>
<tr>
<td>Robert et al. (6)</td>
<td>196</td>
<td>Trastuzumab + paclitaxel + carboplatin</td>
<td>First line</td>
<td>52</td>
<td>10.7</td>
<td>35.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trastuzumab + paclitaxel</td>
<td></td>
<td></td>
<td>36*</td>
<td>7.1*</td>
</tr>
<tr>
<td>BCIRG 007 (7)</td>
<td>263</td>
<td>Trastuzumab + docetaxel + carboplatin</td>
<td>First line</td>
<td>72</td>
<td>10.4</td>
<td>37.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trastuzumab + docetaxel</td>
<td></td>
<td></td>
<td>72</td>
<td>10.4</td>
</tr>
<tr>
<td>HERNATA (8)</td>
<td>284</td>
<td>Trastuzumab + docetaxel</td>
<td>First line</td>
<td>59</td>
<td>12.4</td>
<td>35.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trastuzumab + vinorelbine</td>
<td></td>
<td></td>
<td>59</td>
<td>15.3</td>
</tr>
<tr>
<td>Burstein et al. (9)</td>
<td>81</td>
<td>Trastuzumab + paclitaxel/docetaxel</td>
<td>First line</td>
<td>58</td>
<td>6.0</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trastuzumab + vinorelbine</td>
<td></td>
<td></td>
<td>66</td>
<td>8.5*</td>
</tr>
<tr>
<td>CLEOPATRA (10,11)</td>
<td>808</td>
<td>Trastuzumab + pertuzumab + docetaxel</td>
<td>First line</td>
<td>80</td>
<td>18.5</td>
<td>56.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trastuzumab + docetaxel</td>
<td></td>
<td></td>
<td>69*</td>
<td>12.4*</td>
</tr>
<tr>
<td>MARIANNE (12)</td>
<td>1,095</td>
<td>T-DM1 + pertuzumab</td>
<td>First line</td>
<td>64.2</td>
<td>15.2</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T-DM1 + placebo</td>
<td></td>
<td></td>
<td>59.7</td>
<td>14.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T-DM1 + taxane</td>
<td></td>
<td></td>
<td>67.9</td>
<td>13.7</td>
</tr>
<tr>
<td>GBG26 (13)</td>
<td>156</td>
<td>Trastuzumab + capecitabine</td>
<td>Second line</td>
<td>48</td>
<td>8.2</td>
<td>25.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capecitabine</td>
<td></td>
<td></td>
<td>27*</td>
<td>5.6*</td>
</tr>
<tr>
<td>Geyer et al. (14)</td>
<td>324</td>
<td>Lapatinib + capecitabine</td>
<td>Second line</td>
<td>22</td>
<td>8.4</td>
<td>17.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capecitabine</td>
<td></td>
<td></td>
<td>14*</td>
<td>4.4*</td>
</tr>
<tr>
<td>EMILA (15)</td>
<td>991</td>
<td>T-DM1</td>
<td>Second line</td>
<td>44</td>
<td>9.6</td>
<td>30.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lapatinib + capecitabine</td>
<td></td>
<td></td>
<td>31*</td>
<td>6.4*</td>
</tr>
<tr>
<td>TH3RESA (16)</td>
<td>602</td>
<td>T-DM1</td>
<td>Third line</td>
<td>31</td>
<td>6.2</td>
<td>22.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Physician’s choice</td>
<td></td>
<td></td>
<td>9*</td>
<td>3.3*</td>
</tr>
<tr>
<td>EGF104900 (17,18)</td>
<td>296</td>
<td>Lapatinib + trastuzumab</td>
<td>Beyond third line</td>
<td>10.3</td>
<td>11.1</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lapatinib</td>
<td></td>
<td></td>
<td>6.9</td>
<td>8.1*</td>
</tr>
</tbody>
</table>

*, Statistically significant with P<0.05. TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reach.
196 patients to trastuzumab and paclitaxel with or without carboplatin. Though, the addition of carboplatin to paclitaxel and trastuzumab improved objective response rate (ORR) (52% vs. 36%) and PFS (10.7 vs. 7.1 months) in women with HER2-positive MBC, no significant difference in OS (35.7 vs. 32.2 months, P=0.76) and more hematologic toxicity was observed.

Similarly, The Breast Cancer International Research Group (BCIRG) 007 study researched trastuzumab and docetaxel with or without carboplatin, and found that adding carboplatin did not enhance antitumor activity (7).

Two phase III trials compared trastuzumab plus taxane or vinorelbine as first-line therapy (8,9). Both trastuzumab/taxane and trastuzumab/vinorelbine treatments were efficacy and tolerability for HER2-positive MBC. And, they both could be considered as an alternative first-line option.

Pertuzumab is a recombinant, humanized monoclonal antibody that bind to a different HER2 epitope than trastuzumab, is known as an inhibitor of heterodimerization of the HER receptors. Phase I/II clinical trial by Cortés et al. (20) showed pertuzumab as monotherapy or in combination with chemotherapy was not effective in patient that progressed during therapy with trastuzumab. But, in the phase III trial CLEOPATRA, pertuzumab added to the first-line treatment standard of docetaxel plus trastuzumab and challenged classic. Patients (n=808) with HER2-positive MBC randomized to receive trastuzumab plus docetaxel plus placebo (control group) or trastuzumab plus docetaxel plus pertuzumab (pertuzumab group) as first-line therapy. The median independently assessed PFS for addition of pertuzumab was prolonged by 6.1 months (12.4 vs. 18.5 months, P<0.001) (10). The final prespecified OS results with a median follow-up of 50 months reported 56.5 months in the pertuzumab group and significantly improved compared with 40.8 months in the control group (P<0.001) (11). Dang et al. (21,22) performed a phase II study of weekly paclitaxel alone with trastuzumab and pertuzumab in 69 HER2-positive MBC patients (74% and 26% treated in first- and second-line), the result showed weekly paclitaxel added to trastuzumab and pertuzumab was associated with a favorable OS and PFS and offered an alternative to docetaxel-based therapy.

The MARIANNE trial (21) showed that T-DM1 arm and T-DM1 plus pertuzumab arm had noninferior PFS compared with trastuzumab plus taxane (T-DM1, 14.1 months; T-DM1 plus pertuzumab, 15.2 months; trastuzumab plus taxane, 13.7 months) and neither experimental arm showed PFS superiority to trastuzumab plus taxane for first-line treatment of HER2-positive MBC. The incidence of grade ≥3 adverse events was significant higher in the trastuzumab plus taxane arm (54.1%) versus the T-DM1 arm (45.4%) and T-DM1 plus pertuzumab arm (46.2%). In the T-DM1 arms, there were fewer patients discontinued treatment because of adverse events and health-related quality of life was maintained for longer.

Therefore, nowadays pertuzumab, trastuzumab plus docetaxel is the standard treatment in the first-line therapy for HER2-positive MBC, T-DM1 may be an alternative.

Second-line therapy

Patients in MBC with the first-line therapy always recurred or progressed. Therapeutic options with evidenced based include continuation of trastuzumab with a different chemotherapy parter. The phase III trial by German Breast Group 26 study (13) showed continuation of trastuzumab plus capecitabine had a significant improvement in overall response and TTP compared with capecitabine alone in patients with HER-2-positive breast cancer who experienced progression during trastuzumab treatment, but, the OS was not statistically significant (25.5 vs. 20.4 months, P=0.257).

Lapatinib is an orally available small molecule tyrosine kinase inhibitor of both epidermal growth factor receptor (EGFR) and HER2. The Canadian-led MA.31 study (23) by the NCIC clinical trials group, compared lapatinib with trastuzumab, both combined with a taxane in the first-line setting showed lapatinib with taxane therapy is associated with a shorter PFS compared to trastuzumab with taxane. But, lapatinib plus capecitabine is a choice for the patients progressed for trastuzumab. An phase III trial by Geyer et al. (14) comparing lapatinib plus capecitabine versus capecitabine alone in patients who have progressed on prior trastuzumab-based therapy, in 2006, interim analyzed that there was a significant improvement in PFS (8.4 vs. 4.4 months, P<0.001). And, the improvement was got without an increase in serious toxic effects or symptomatic cardiac event. Although premature enrollment termination and subsequent crossover resulted in insufficient power to detect differences in OS, the final exploratory analyses demonstrated a trend toward a survival advantage with lapatinib plus capecitabine (24).

T-DM1 is a HER2-positive directed antibody drug conjugate that incorporates the HER2-targeted anti-tumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The EMILA trial (15),
comparing T-DM1 and lapatinib-capecitabine for patients who had previously been treated with trastuzumab and taxane, reported a statistically significant OS advantage in favor of T-DM1 at the second interim analysis in 2012, and it led to registration and rapid clinical adoption of T-DM1. In 2017, the EMILA final analysis showed median OS was longer with T-DM1 than with lapatinib-capecitabine (29.9 vs. 25.9 months), though 136 (27%) of 496 patients crossed over from control to T-DM1 after the second interim overall survival analysis. Additional, the rates of grade 3 or 4 adverse events were numerically higher in lapatinib plus capecitabine versus T-DM1 (57% vs. 41%). But, thrombocytopenia and increased serum aminotransferase levels were favored for T-DM1.

So, at the present time, T-DM1 is the standard treatment in the second-line therapy for HER2-positive MBC.

Third-line therapy and beyond

Phase III trial for anti-HER2 therapy in the third-line setting is seldom reported. The TH3RESA trial (16) is the only one we know. Eligible patients were men and women (n =602) previously treated with both trastuzumab and lapatinib (advanced setting) and a taxane (any setting) and with progression on two or more HER2-directed regimens in the advanced setting. Patients were randomized in a 2:1 fashion to T-DM1 and physician’s choice of therapy. At data cutoff, 47% patients in the physician’s choice group had crossed over to T-DM1. OS was significantly longer with T-DM1 versus treatment of physician’s choice (22.7 vs. 15.8 months, P=0.0007).

The EGF104900 trial (17) is a phase III for patients who received a median of three prior trastuzumab-containing treatment, compared the combination of lapatinib plus trastuzumab to lapatinib alone. It reported lapatinib plus trastuzumab showed superiority to lapatinib monotherapy in PFS (11.1 vs. 8.1 weeks, P=0.011) and OS (14 vs. 9.5 months, P=0.026) (17,18). Thus offer a chemotherapy-free option with an acceptable safety profile to patients with heavily pretreated HER2-positive MBC.

Hormone receptor(HR)-positive tumors

For patients with HR-positive and HER2-positive breast cancer who have light tumor burden or be old, the combination of anti-HER2 therapy and endocrine therapy may considered.

The combination of trastuzumab and endocrine therapy had been tested in postmenopausal HR-positive and HER2-positive MBC patients. The TAnDEM study (25) showed trastuzumab plus anastrozole having an improvement PFS than anastrozole alone(4.8 vs. 2.4 months, P<0.001), but non-significant increase in OS (28.5 vs. 23.9 months). The eLEcTRA trial (26) compared efficacy and safety of trastuzumab plus letrozole to letrozole alone in patients with HER2-positive and HR-positive MBC as first-line treatment and demonstrated that the combination of trastuzumab and letrozole was a safe and effective treatment option.

A letrozole and lapatinib combination was tested in the first-line setting for HR-positive HER2-positive MBC. Results in 219 patients, letrozole plus lapatinib significantly reduced the risk of disease progression versus letrozole plus placebo [hazard ratio (HR) =0.71; 95% CI, 0.53 to 0.96; P=0.019]; median PFS was 8.2 vs. 3.0 months, respectively (27).

The ALTERNATIVE study (28) evaluated the efficacy and safety of dual HER2 blockade (lapatinib plus trastuzumab) plus aromatase inhibitor (AI) in postmenopausal women with HR-positive and HER2-positive MBC who received prior endocrine therapy and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. LAP + TRAS + AI showed a more superior PFS than TRAS + AI (11 vs. 5.7 months, P=0.0064). And LAP + AI had a more superior PFS than TRAS + AI (8.3 vs. 5.7 months, P=0.0361). Overall response rate, clinical benefit rate, and OS also favored LAP + TRAS + AI.

Although improvements in PFS are seen with the combination of anti-HER2 therapy and endocrine therapy for this subset of patients with HR-positive and HER2-positive disease, only one study has demonstrated an improvement in OS. So, the use of such an approach has to be weighed and only offers a safe chemotherapy-sparing alternative treatment regimen for patient without aggressive disease and who are not candidates for chemotherapy.

New agents in anti-HER2

Neratinib is an orally active, irreversible inhibitor of the HER-2 tyrosine kinase that blocks signal transduction through a broad spectrum of 3 receptors, erbB-1, erbB-2 and erbB-4 (29,30). The first open-label multicenter phase II trial with neratinib monotherapy for patients with advanced HER2-positive breast cancer was reported in 2010. Patients were divided into two cohorts, the prior trastuzumab cohort (n=66) and no prior trastuzumab cohort.
The results showed 16-week PFS rates were 59% for patients with prior trastuzumab treatment and 78% for patients with no prior trastuzumab treatment. Median PFS was 22.3 and 39.6 weeks. Diarrhea was the most frequent grades 3 to 4 adverse event, occurring in 30% of patients with prior trastuzumab treatment and in 13% of patients with no prior trastuzumab treatment (31). A phase I/II trial (32) had been conducted, evaluating the role of neratinib plus capecitabine for patients with trastuzumab-pretreated HER2-positive MBC. The objective response rate (ORR) was 64% (n=39 of 61) in patients with no prior lapatinib exposure and 57% (n=4 of 7) in patients previously treated with lapatinib. Median PFS was 40.3 and 35.9 weeks. The NEFERT-T Randomized Clinical Trial (33) showed in first-line HER2-positive MBC, neratinib-paclitaxel was not superior to trastuzumab-paclitaxel in terms of PFS. But, neratinib-paclitaxel may delay the onset and reduce the frequency of central nervous system progression. These results need to be confirmed by large-scale randomized trials.

Afatinib is also an oral small molecule HER family tyrosine kinase inhibitor and has the ability to cross the blood-brain barrier, could play a role in patients with brain metastases from breast cancer (34). The Lux-Breast trials are evaluating afatinib in additional clinical settings. Compared with trastuzumab-based therapy, afatinib had no advantage for patients with HER2-positive MBC who had progressed on trastuzumab (35). The Lux-Breast III trial (36) is evaluating afatinib monotherapy or afatinib plus vinorelbine compared with the investigators' choice of treatment for patients with HER2-positive MBC and progressive brain metastasis who have progressed on prior trastuzumab or lapatinib based therapy. Though patient benefit with afatinib-containing treatments was not different from that in patients given investigator’s choice of treatments, adverse events were frequent and afatinib-containing treatments seemed to be less well tolerated. A phase II small exploratory study showed afatinib combined with letrozole was able to induce disease stabilization in 54% of hormone-refractory MBC patients previously progressing on letrozole (37).

So far, Neratinib and Afatinib didn’t show superiority for MBC, how to make them play an important role needs to be further practiced.

Margetuximab is a Fc-modified anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A phase I study in patients with HER2-positive MBC showed margetuximab was well-tolerated and has promising single-agent activity. Further development efforts of single agent or in combination with other therapeutic agents are ongoing (38).

MM-302 is a HER2-targeted PEGylated liposome that encapsulates doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells. The combination of MM-302 and trastuzumab induced synergistic antitumor activity in HER2-overexpressing xenograft models of breast (39). A randomized Phase 2 trial (HERMIONE) of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive MBC is ongoing (40).

SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA. In vivo antitumor studies in breast cancer xenograft models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models (41). Clinical trial (NCT03262935) of SYD985 vs. Physician’s Choice in participants with HER2-positive locally advanced or MBC in third line-setting and beyond is conducted.

New combinations (with mTOR inhibitors or PI3K inhibitors)

Mutations in the PI3K pathway are frequent in breast cancer, causing resistance to HER 2-targeted agents. PI3K is downstream from HER2 and mTOR is downstream from PI3K, target this pathway may be an important step in overcoming trastuzumab resistance in HER2-positive MBC (42,43). BOLERO-1 and BOLERO-3 trials had evaluated mTOR inhibition in HER2-positive MBC. The BOLERO-3 trials showed addition of everolimus to trastuzumab plus vinorelbine significantly prolongs PFS (7.0 vs. 5.78, P=0.0067) in patients with trastuzumab-resistant and taxane-pretreated, HER2-positive MBC. But, serious adverse events were reported in the everolimus group (44). The phase III BOLERO-1 trial compares paclitaxel and trastuzumab with or without everolimus for first-line treatment of women with HER2-positive MBC (45). Although PFS was not significantly different between groups in the full population, the 7.2 months prolongation was noted with the addition of everolimus in the HR-negative HER2-positive population.

Pilaralisib (SAR245408) is a pan-class I PI3K inhibitor. A phase I/II study of pilaralisib in combination with trastuzumab or paclitaxel plus trastuzumab was conducted
on patients with HER2-positive MBC who had progressed on a prior trastuzumab-containing regimen and resulted that pilaralisib in combination with trastuzumab with or without paclitaxel had an acceptable safety profile and with clinical activity in the paclitaxel arm (46).

**Anti-HER2 therapy in HER2 low-or non-expression breast cancer**

In adjuvant, the National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 demonstrated the efficacy of adjuvant trastuzumab added to chemotherapy not only for HER2-positive breast cancer but also, surprisingly, for HER2-negative breast cancer (47-49) and which facilitated the NSABP B-47 trial for testing trastuzumab in HER2 low-expression patients (HER2 IHC score 1+, 2+ and FISH negative). Unfortunately, the results showed that adjuvant trastuzumab added to chemotherapy didn’t receive additional benefit, but increased severe toxicities (50).

Though some preclinical models showed pertuzumab inhibits tumor growth in the absence of HER2 overexpression, unlike trastuzumab, presumably by preventing ligand-stimulated HER2 heterodimer formation, a phase II multicenter, randomized study about pertuzumab in patients with HER2-negative MBC showed a limited efficacy (51).

More recently, research showed HER2 somatic mutations in breast cancer patients activating mutations that likely drive tumorigenesis, but the majority of HER2 somatic mutations had not been associated with concurrent HER2 gene amplification (52). Preclinical data suggest that functionally activating HER2 mutations may drive and maintain cancers and HER2 mutations may similarly confer sensitivity to HER2-directed drugs (53). Case report showed a triple-negative (ER/PR/HER2) inflammatory breast cancer but HER2 mutated was response to anti-HER2 therapy (lapatinib and capecitabine) (54).

Trastuzumab deruxtecan (DS-8201) is an ADC, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload. In a phase I study showed that in 23 evaluable patients (advanced breast and gastric or gastro-oesophageal tumours), including six low HER2-expressing patients, ten patients achieved an objective response (43%, 95% CI, 23.2–65.5) and disease control was achieved in 21 (91%) of 23 patients (55). So, MBC with HER2 mutation-positive but HER2 negative may benefit from existing HER2-targeted drugs, further clinical studies are needed. Trastuzumab deruxtecan is worthy of further study for patients with low HER2-expressed.

**Conclusions**

The landscape of treatment for HER2-positive MBC continues to be refined, and evolves. Nowadays, the first line treatment is pertuzumab, trastuzumab plus docetaxel, and T-DM1 has great potential. However, drug resistance is inevitable in treatment. T-DM1 is the standard treatment in the second-line setting and beyond nowadays. For HR-positive and HER2-positive MBC patients who without aggressive disease and are not candidates for chemotherapy, the combination of dual anti-HER2 therapy and endocrine therapy may considered. The introduction of novel agents offers clinicians the ability to prolonged inhibition of the HER2 pathway across multiple lines of treatment. Active clinical trials of different agents combinations will hopefully result in continued improvements in outcomes for HER2-positive MBC patients. Then, patients for HER2-negative but HER2 mutation-positive may have benefit from anti-HER2 therapy.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**

5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of


Cite this article as: Yao M, Fu P. Advances in anti-HER2 therapy in metastatic breast cancer. Chin Clin Oncol 2018;7(3):27. doi: 10.21037/cco.2018.05.04